2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, MA USA

mAbs

Volumn 4, Issue 5, 2012, Pages 562-570

  Ho, Mitchell ^a   Royston, Ivor ^b   Beck, Alain ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Forward Ventures   (United States)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antibody drug conjugates; Biobetters; Biosimilars; Bispecific antibodies; Cetuximab Erbitux; Immunotoxins; Monoclonal antibodies; Rituximab Rituxan; Trastuzumab Herceptin; Tumor penetration

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANGIOPOIETIN; B CELL ACTIVATING FACTOR; BEVACIZUMAB; BISPECIFIC ANTIBODY; BRENTUXIMAB VEDOTIN; CANCER ANTIBODY; CD20 ANTIBODY; CETUXIMAB; CHEMOKINE RECEPTOR CCR4; DOCETAXEL; GELATINASE A; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMC 11F 8; IMMUNOGLOBULIN G; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; IPILIMUMAB; IRINOTECAN; NECITUMUMAB; OFATUMUMAB; PANITUMUMAB; PERTUZUMAB; RANTES; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BILE DUCT CARCINOMA; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER THERAPY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLON TUMOR; COMPARATIVE STUDY; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; HYDROLYSIS; IMMUNOGENICITY; IN VITRO STUDY; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; LYMPHOMA; LYMPHOMA CELL; MESOTHELIOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REMISSION; WNT SIGNALING PATHWAY; XENOGRAFT;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS;

EID: 84866529024     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21521     Document Type: Conference Paper

References (64)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0.
2. Dillman RO, Shawler DL, Sobol RE, Collins HA, Beauregard JC, Wormsley SB, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982; 59:1036-45; PMID:6896161.
3. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984; 2:881-91; PMID:6379121.
4. Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16:199-210; PMID:2658083.
5. Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982; 59:1-11; PMID:7032624.
6. Glassy MC, Handley HH, Hagiwara H, Royston I. UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc Natl Acad Sci U S A 1983; 80:6327-31; PMID:6604917; http://dx.doi.org/10.1073/ pnas.80.20.6327.
7. Glassy MC, Handley HH, Surh C, Royston I. Genetically stable human hybridomas secreting tumor-reactive human monoclonal IgM. Cancer Invest 1987; 5:449-57; PMID:3501329; http://dx.doi.org/10.3109/07357908709032902.
8. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306:517-22; PMID:6173751; http://dx.doi.org/10.1056/ NEJM198203043060906.
9. Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25:705-8; PMID:9191187.
10. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8; PMID:10845926.
11. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
13. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48:673-83; PMID:10752475; http://dx.doi. org/10.1007/ s002620050016.
14. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747.
15. Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; In press; PMID:22561895; http://dx.doi.org/10.1016/j. drudis.2012.04.006.
16. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi. org/10.1016/j.ccr.2005.03.003.
17. Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216-27; PMID:18275813; http://dx.doi.org/10.1016/j.str.2007.11.009.
18. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http:// dx.doi.org/10.1016/S1535- 6108(04)00083-2.
19. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216.
20. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482-501; PMID:19075687; http:// dx.doi.org/10.2174/138920108786786411.
21. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39; PMID:21034674.
22. Beck A, Senter P, Chari R. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. MAbs 2011; 3:331-7; PMID:21691144; http://dx.doi.org/10.4161/mabs.3.4.16612.
23. Niculescu-Duvaz I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 2010; 12:350-60; PMID:20521224.
24. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161-72; PMID:21441786; http://dx.doi.org/10.4161/mabs.3.2.14960.
25. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30:184-9; http://dx.doi.org/10.1038/nbt.2108; PMID:22267010.
26. Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637-46; PMID:22510259; http://dx.doi.org/10.1021/ac3002885.
27. Wang C, He X, Zhou B, Li J, Li B, Qian W, et al. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs 2011; 3:67-75; PMID:21051930; http://dx.doi.org/10.4161/mabs.3.1. 14021.
28. Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011; 128:2020-30; PMID:20635390; http://dx.doi.org/10.1002/ijc.25557.
29. Torisawa YS, Mosadegh B, Cavnar SP, Ho M, Takayama S. Transwells with Microstamped Membranes Produce Micropatterned Two-Dimensional and Three-Dimensional Co-Cultures. Tissue Eng Part C Methods 2010; 17:61-7; PMID:20673133; http://dx.doi.org/10.1089/ten.tec.2010.0305.
30. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011; 136:473-8; PMID:20967331; http://dx.doi.org/10.1039/ c0an00609b.
31. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 2011; 6:e14640; PMID:21305058; http://dx.doi.org/10.1371/journal.pone.0014640.
32. Kim H, Phung Y, Ho M. Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model. PLoS One 2012; 7:e39556; PMID:22737246; http://dx.doi.org/10.1371/journal.pone. 0039556.
33. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011; 71:7080-90; PMID:21990319; http://dx.doi.org/10.1158/0008-5472. CAN-11-2009.
34. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med 2009; 206:2779-93; PMID:19858324; http://dx.doi.org/10.1084/jem.20091107.
35. Vire B, David A, Wiestner A. TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol 2011; 187:4040-50; PMID:21908732; http://dx.doi.org/10. 4049/jimmunol.1100532.
36. Hofer T, Thomas JD, Burke TR Jr., Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci U S A 2008; 105:12451-6; PMID:18719095; http://dx.doi.org/10.1073/pnas.0800800105.
37. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617.
38. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-37; PMID:17059365; http://dx.doi. org/10.1146/annurev.med.58.070605.115320.
39. Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma 2011; 52(Suppl 2):87-90; PMID:21504287; http://dx.doi.org/10.3109/10428194.2011.573039.
40. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30:1822-8; PMID:22355053; http://dx.doi.org/10.1200/ JCO.2011.38.1756.
41. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53; PMID:17945478; http://dx.doi.org/10.1016/j.ejca.2007.08.028.
42. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144-9; PMID:17785569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0869.
43. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-7; PMID:11474661; http:// dx.doi.org/10.1056/NEJM200107263450402.
44. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719-29; PMID:16061911; http://dx.doi.org/10.1200/JCO.2005.11.437.
45. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15:5274-9; PMID:19671873; http://dx.doi.org/10.1158/1078-0432.CCR-09- 0062.
46. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006; 177:8822-34; PMID:17142785.
47. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 2008; 105:11311-6; PMID:18678888; http://dx.doi.org/10.1073/ pnas.0804851105.
48. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113:3792-800; PMID:18988862; http://dx.doi.org/10.1182/blood-2008-08-173195.
49. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 2011; 108:5742-7; PMID:21436054; http://dx.doi. org/10.1073/pnas.1102746108.
50. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86:10024-8; PMID:2513569; http:// dx.doi.org/10.1073/ pnas.86.24.10024.
51. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35-45; PMID:12509765; http://dx.doi.org/10.1038/nrc971.
52. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035-44; PMID:20439624; http://dx.doi.org/10.1182/blood-2010-01-043737.
53. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388.
54. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011; 17:1685-91; PMID:22057348; http://dx.doi.org/10.1038/ nm.2554.
55. Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res 2011; 44:83-90; PMID:21062101; http://dx.doi.org/10.1021/ar1000633.
56. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009; 15:104-9; PMID:19029979; http://dx.doi.org/ 10.1038/nm.1854.
57. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009; 69:1268-72; PMID:19176373; http://dx.doi.org/10.1158/0008-5472.CAN-08-3116.
58. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730.
59. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas. 0530291100.
60. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5:168-77; PMID:19664991; http://dx.doi.org/10.1016/j.stem.2009. 05.019.
61. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, et al. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 2011; 71:1520-5; PMID:21193546; http://dx.doi.org/10.1158/0008-5472.CAN-10-2817.
62. Gurney A, Hoey T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc Cell 2011; 3:18; PMID:21831306; http://dx.doi.org/10. 1186/2045-824X-3-18.
63. Mross K, Fischer R, Richly H, Scharr D, Buechert M, Stern A, et al. First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. Molecular Cancer Therapeutics 2011; 10: Supplement 1 (Abstract A212). doi: 10.1158/1535-7163.TARG-11-A212.
64. Kanakaraj P, Puffer BA, Yao X-T, Kankanala S, Boyd E, Shah RR, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; In press.